Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

The impact on survival of positive intraoperative pleural lavage cytology in patients with non–small-cell lung cancer Keiju Aokage, MD, Junji Yoshida,

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Electronic Updates for JTO Readers

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival Tom Donnem,

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Teratoma with malignant transformation in the anterior mediastinum

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Upregulation of Hypoxia-Inducible Factor-1α mRNA and its Clinical Significance in Non- small Cell Lung Cancer Tomofumi Yohena, MD, Ichiro Yoshino, MD,

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

It’s All in the “Swerve of the Curve”

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Who should decide margin length in pulmonary excision of lung cancer?

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer Katsuhiko Shimizu, MD, PhD, Masao Nakata, MD, PhD, Yuji Hirami, MD, PhD, Takuro Yukawa, MD, Ai Maeda, MD, Kazuo Tanemoto, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 5, Pages 585-590 (May 2010) DOI: 10.1097/JTO.0b013e3181d60fd7 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Immunohistochemical staining for COX-2 (A) and Foxp3 (B). Journal of Thoracic Oncology 2010 5, 585-590DOI: (10.1097/JTO.0b013e3181d60fd7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier recurrence-free survival curve according to COX-2 expression, log-rank p = 0.017. Journal of Thoracic Oncology 2010 5, 585-590DOI: (10.1097/JTO.0b013e3181d60fd7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Relationship between the expression status of COX-2 and tumor-infiltrating Foxp3+ regulatory T-cells, *p < 0.001. Journal of Thoracic Oncology 2010 5, 585-590DOI: (10.1097/JTO.0b013e3181d60fd7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Kaplan-Meier recurrence-free survival curve according to Foxp3 expression, log-rank p = 0.004. Journal of Thoracic Oncology 2010 5, 585-590DOI: (10.1097/JTO.0b013e3181d60fd7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Kaplan-Meier recurrence-free survival curve in node-negative non-small cell lung cancer (NSCLC) according to (A) COX-2 expression and (B) Foxp3 expression in node negative patients, log-rank p = 0.024 and p < 0.001. Journal of Thoracic Oncology 2010 5, 585-590DOI: (10.1097/JTO.0b013e3181d60fd7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions